New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
14:00 EDTHALO, BAXBaxter, Halozyme announce favorable FDA panel recommendation on HyQvia
Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the Blood Products Advisory Committee of the FDA voted 15-1 that HyQvia, Baxter’s investigational subcutaneous treatment for patients with primary immunodeficiency, has a favorable risk/benefit profile. ''We are hopeful that the positive support for HyQvia is the next step toward providing a new treatment option for patients with primary immunodeficiency in the United States. We look forward to working closely with the FDA as it completes its review,'' said Ludwig Hantson, Ph.D., president of Baxter BioScience. HyQvia was approved in Europe in 2013 for adults with primary immunodeficiency syndromes and myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. HyQvia is a product consisting of human normal immunoglobulin and recombinant human hyaluronidase, licensed from Halozyme.
News For BAX;HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
07:15 EDTBAXLeerink to hold a conference
Subscribe for More Information
February 2, 2016
09:24 EDTBAXBaxter: 1Q16 should be weakest quarter of FY16
Subscribe for More Information
08:53 EDTBAXBaxter sees FY16 CapEx $900M
Says does not anticipate any sales in 2016 in IPS. Sees FY16 surgical franchise sales growth 2%-3%. Sees FY16 renal business sales growth roughly 3%. Sees FY16 operating margin roughly 11%. Sees FY16 interest expense roughly $90M. Sees FY16 adjusted tax rate 19%-20%. Sees FY16 average share count roughly 540M shares. Sees FY16 CapEx $900M. Sees FY16 free cash flow $500M. Sees FY16 operating cash flow roughly $1.4B. Guidance taken from Q4 earnings conference call.
07:04 EDTBAXBaxter sees FY16 EPS ex-items $1.46-$1.54, consensus $1.42
Subscribe for More Information
07:03 EDTBAXBaxter sees Q1 EPS ex-items 28c-30c, consensus 32c
Subscribe for More Information
07:02 EDTBAXBaxter reports Q4 adjusted EPS 43c, consensus 32c
Subscribe for More Information
February 1, 2016
14:32 EDTBAXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus 64c... Pfizer (PFE), consensus 52c... United Parcel Service (UPS), consensus $1.42... Dow Chemical (DOW), consensus 70c... Emerson Electric (EMR), consensus 51c... Archer-Daniels-Midland (ADM), consensus 66c... Baxter (BAX), consensus 32c... Sirius XM (SIRI), consensus 3c... Royal Caribbean Cruises (RCL), consensus 92c... Ally Financial (ALLY), consensus 51c... Michael Kors (KORS), consensus $1.46... ADT Corp. (ADT), consensus 46c.
10:05 EDTHALOOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Acadia (ACHC) initiated with an Overweight at KeyBanc... Altisource Residential (RESI) initiated with a Neutral at Nomura... Colony Starwood Homes (SFR) initiated with a Buy at Nomura... EyeGate (EYEG) initiated with a Buy at Rodman & Renshaw... Fortinet (FTNT) initiated with an Outperform at Northland... Halozyme (HALO) initiated with a Buy at Canaccord... Lendingtree (TREE) initiated with an Outperform at Northland... Lindblad Expeditions (LIND) initiated with an Outperform at Credit Suisse... Summit Therapeutics (SMMT) initiated with a Buy at Canaccord... VolitionRx (VNRX) initiated with a Buy at Rodman & Renshaw.
08:09 EDTBAXOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.
07:20 EDTHALOHalozyme initiated with a Buy at Canaccord
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use